Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F, Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, CatronJournal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(20)30112-1
Date:
April, 2020
File:
PDF, 783 KB
2020
File converter
More search results
More benefits 
